Right ventricular remodeling and clinical outcomes following transcatheter tricuspid valve intervention.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
02 2024
Historique:
revised: 20 08 2023
received: 07 04 2023
accepted: 05 10 2023
medline: 31 1 2024
pubmed: 27 10 2023
entrez: 27 10 2023
Statut: ppublish

Résumé

Characterize the impact of residual tricuspid regurgitation (TR) on right ventricle (RV) remodeling and clinical outcomes after transcatheter tricuspid valve intervention. We performed a single-center retrospective analysis of transcatheter tricuspid valve repair (TTVr) or replacement (TTVR) patients. The primary outcomes were longitudinal tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), pulmonary artery systolic pressure (PASP), and RV dimensions (RVd). We used multivariable linear mixed models to evaluate association with replacement versus repair and degree of TR reduction with changes in these echo measures over time. Multivariable Cox regression was used to identify associations between changes in these echo measures and a composite clinical outcome of death, heart failure hospitalization, or re-do tricuspid valve intervention. We included a total of 61 patients; mean age was 77.5 ± 11.7 and 62% were female. TTVR was performed in 25 (41%) and TTVr in 36 (59%). Initially, 72% (n = 44) had ≤ severe TR and 28% (n = 17) had massive or torrential TR. The median number of follow up echos was 2: time to 1st follow-up was 50 days (interquartile range [IQR]: 20, 91) and last follow-up was 147 (IQR: 90, 327). Median TR reduction was 1 (IQR: 0, 2) versus 4 (IQR: 3, 6) grades in TTVr versus TTVR (p < 0.0001). In linear mixed modeling, TTVR was associated with decline in TAPSE and PASP, and TR reduction was associated with decreased RVd. In multivariable Cox regression, greater RVd was associated with the clinical outcome (hazard ratio: 9.27, 95% confidence interval: 1.23-69.88, p = 0.03). Greater TR reduction is achieved by TTVR versus TTVr, which is in turn associated with RV reverse remodeling. RV dimension in follow-up is associated with increased risk of a composite outcome of death, heart failure hospitalization, or re-do tricuspid valve intervention.

Identifiants

pubmed: 37890014
doi: 10.1002/ccd.30850
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-375

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12:433-442.
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. JACC. 2019;74:2998-3008.
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833-1842.
Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. Circulation. 2009;120:1672-1678.
Di Mauro M, Foschi M, Tancredi F, et al. Additive and independent prognostic role of abnormal right ventricle and pulmonary hypertension in mitral-tricuspid surgery. Int J Cardiol. 2018;252:39-43.
Karam N, Mehr M, Taramasso M, et al. Value of echocardiographic right ventricular and pulmonary pressure assessment in predicting transcatheter tricuspid repair outcome. JACC Cardiovasc Interv. 2020;13:1251-1261.
Schlotter F, Miura M, Kresoja KP, et al. Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention. 2021;17:e343-e352.
Patlolla SH, Schaff HV, Greason KL, et al. Early right ventricular reverse remodeling predicts survival after isolated tricuspid valve surgery. Ann Thorac Surg. 2021;112:1402-1409.
Orban M, Wolff S, Braun D, et al. Right ventricular function in transcatheter edge-to-edge tricuspid valve repair. JACC Cardiovasc Imaging. 2021;14(12):2477-2479.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the american Society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30(4):303-371.
Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging. 2017;18:1342-1343.
Mesnier J, Alperi A, Panagides V, et al. Transcatheter tricuspid valve interventions: current devices and associated evidence. Prog Cardiovasc Dis. 2021;69:89-100.
Fukuda S, Gillinov AM, McCarthy PM, et al. Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2006;114:I582-I587.
Fukuda S, Song JM, Gillinov AM, et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2005;111:975-979.
Utsunomiya H, Itabashi Y, Mihara H, et al. Usefulness of 3D echocardiographic parameters of tricuspid valve morphology to predict residual tricuspid regurgitation after tricuspid annuloplasty. Eur Heart J Cardiovasc Imaging. 2017;18:809-817.
van den Enden AJM, Bastos MB, Schreuder JJ, Daemen J, Van Mieghem NM. Invasive cardiomechanics during transcatheter edge-to-edge repair for massive tricuspid regurgitation using biventricular pressure-volume loop monitoring. JACC Case Rep. 2021;3:1883-1887.
Muntané-Carol G, Alperi A, Faroux L, et al. Transcatheter interventions for tricuspid valve disease: what to do and who to do it on. Can J Cardiol. 2021;37:953-967.
Demir OM, Regazzoli D, Mangieri A, et al. Transcatheter tricuspid valve replacement: principles and design. Front Cardiovasc Med. 2018;5:129.
Orban M, Braun D, Deseive S, et al. Transcatheter edge-to-edge repair for tricuspid regurgitation is associated with right ventricular reverse remodeling in patients with right-sided heart failure. JACC Cardiovasc Imaging. 2019;12:559-560.
Amat-Santos IJ, Estévez-Loureiro R, Sánchez-Recalde A, et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023;19(5):e450-e452.
Dietz MF, Prihadi EA, van der Bijl P, Marsan NA, Delgado V, Bax JJ. Prognostic implications of staging right heart failure in patients with significant secondary tricuspid regurgitation. JACC Heart Fail. 2020;8(8):627-636.
Dietz MF, Prihadi EA, van der Bijl P, et al. Prognostic implications of right ventricular remodeling and function in patients with significant secondary tricuspid regurgitation. Circulation. 2019;140:836-845.
Berman M, Gopalan D, Sharples L, et al. Right ventricular reverse remodeling after pulmonary endarterectomy: magnetic resonance imaging and clinical and right heart catheterization assessment. Pulm Circ. 2014;4:36-44.
Waziri F, Ringgaard S, Mellemkjaer S, et al. Long-term changes of right ventricular myocardial deformation and remodeling studied by cardiac magnetic resonance imaging in patients with chronic thromboembolic pulmonary hypertension following pulmonary thromboendarterectomy. Int J Cardiol. 2020;300:282-288.
Sano H, Tanaka H, Motoji Y, et al. Right ventricular relative wall thickness as a predictor of outcomes and of right ventricular reverse remodeling for patients with pulmonary hypertension. Int J Cardiovasc Imaging. 2017;33:313-321.
Sarashina T, Nakamura K, Akagi S, et al. Reverse right ventricular remodeling after lung transplantation in patients with pulmonary arterial hypertension under combination therapy of targeted medical drugs. Circ J. 2017;81:383-390.

Auteurs

Lyle Dershowitz (L)

Division of Internal Medicine, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Matthew K Lawlor (MK)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Nadira Hamid (N)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Polydoros Kampaktsis (P)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Yuming Ning (Y)

Department of Surgery, Center for Innovation and Outcomes Research, Columbia University Irving Medical Center, New York City, New York, USA.

Torsten P Vahl (TP)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Tamim Nazif (T)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Omar Khalique (O)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Vivian Ng (V)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Paul Kurlansky (P)

Department of Surgery, Center for Innovation and Outcomes Research, Columbia University Irving Medical Center, New York City, New York, USA.

Martin Leon (M)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Rebecca Hahn (R)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Susheel Kodali (S)

Division of Cardiology, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.
Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Isaac George (I)

Structural Heart & Valve Center, New York Presbyterian Hospital-Columbia University Irving Medical Center, New York City, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH